8 assets in Wiskott-Aldrich Syndrome

Therapeutic assets addressing Wiskott-Aldrich Syndrome, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Melphalan Wiskott-Aldrich Syndrome	Washington University School of Medicine	P2	BB (66)
Fludarabine Wiskott-Aldrich Syndrome	Roswell Park Cancer Institute	P2	BB (65)
Thiotepa Wiskott-Aldrich Syndrome	University of Florida	P2	BB (64)
Alemtuzumab Wiskott-Aldrich Syndrome	Washington University School of Medicine	P2	B (62)
Cyclophosphamide Wiskott-Aldrich Syndrome	Roswell Park Cancer Institute	P2	CCC (53)
cd3/cd19 negative allogeneic hematopoietic stem cells Wiskott-Aldrich Syndrome	Paul Szabolcs	P1/2	CCC (48)
Busulfanum Wiskott-Aldrich Syndrome	Masonic Cancer Center, University of Minnesota	N/A	D (30)
Mesna Wiskott-Aldrich Syndrome	Masonic Cancer Center, University of Minnesota	N/A	D (30)